206 related articles for article (PubMed ID: 22212946)
1. Radiotherapeutic strategies in the management of hepatocellular carcinoma.
Lee IJ; Seong J
Oncology; 2011; 81 Suppl 1():123-33. PubMed ID: 22212946
[TBL] [Abstract][Full Text] [Related]
2. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Choi JY
Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
[TBL] [Abstract][Full Text] [Related]
3. Multidisciplinary management of nonresectable hepatocellular carcinoma.
Park HC; Seong J; Tanaka M; Zeng ZC; Lim HY; Guan S; Bae SH; Tak WY
Oncology; 2011; 81 Suppl 1():134-40. PubMed ID: 22212947
[TBL] [Abstract][Full Text] [Related]
4. Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?
Jiang W; Zeng ZC
Oncology; 2013; 84 Suppl 1():69-74. PubMed ID: 23428862
[TBL] [Abstract][Full Text] [Related]
5. Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach.
Bathaix F; Marion D; Cuinet M; Maillard E; Zoulim F; Mornex F; Merle P
Gastroenterol Clin Biol; 2010; 34(4-5):314-8. PubMed ID: 20207091
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of 3-dimensional conformal hypofractionated single high-dose radiotherapy combined with transcatheter arterial chemoembolization for portal vein tumor thrombus in patients with hepatocellular carcinoma].
Wu DH; Chen LH
Ai Zheng; 2004 Jul; 23(7):825-8. PubMed ID: 15248921
[TBL] [Abstract][Full Text] [Related]
8. Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma.
Xu LT; Zhou ZH; Lin JH; Chen Z; Wang K; Wang P; Zhu XY; Shen YH; Meng ZQ; Liu LM
Eur J Surg Oncol; 2011 Mar; 37(3):245-51. PubMed ID: 21195578
[TBL] [Abstract][Full Text] [Related]
9. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM
J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968
[TBL] [Abstract][Full Text] [Related]
10. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma.
Shim SJ; Seong J; Han KH; Chon CY; Suh CO; Lee JT
Liver Int; 2005 Dec; 25(6):1189-96. PubMed ID: 16343071
[TBL] [Abstract][Full Text] [Related]
11. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
12. Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma.
Yoon HI; Seong J
Oncology; 2014; 87 Suppl 1():90-8. PubMed ID: 25427739
[TBL] [Abstract][Full Text] [Related]
13. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
Lencioni R
Crit Rev Oncol Hematol; 2012 Aug; 83(2):216-24. PubMed ID: 22142656
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
15. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
Lencioni R; Chen XP; Dagher L; Venook AP
Oncologist; 2010; 15 Suppl 4():42-52. PubMed ID: 21115580
[TBL] [Abstract][Full Text] [Related]
16. [The treatment of hepatocellular carcinoma. New developments].
Kuiken SD; van Delden OM; Richel DJ; Jansen PL
Ned Tijdschr Geneeskd; 2009 Apr; 153(14):668-72. PubMed ID: 19425326
[No Abstract] [Full Text] [Related]
17. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
Han KH; Kudo M; Ye SL; Choi JY; Poon RT; Seong J; Park JW; Ichida T; Chung JW; Chow P; Cheng AL
Oncology; 2011; 81 Suppl 1():158-64. PubMed ID: 22212951
[TBL] [Abstract][Full Text] [Related]
18. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Kudo M; Imanaka K; Chida N; Nakachi K; Tak WY; Takayama T; Yoon JH; Hori T; Kumada H; Hayashi N; Kaneko S; Tsubouchi H; Suh DJ; Furuse J; Okusaka T; Tanaka K; Matsui O; Wada M; Yamaguchi I; Ohya T; Meinhardt G; Okita K
Eur J Cancer; 2011 Sep; 47(14):2117-27. PubMed ID: 21664811
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Baek KK; Kim JH; Uhm JE; Park SH; Lee J; Park JO; Park YS; Kang WK; Lim HY
Oncology; 2011; 80(3-4):167-74. PubMed ID: 21701230
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hepatocellular carcinoma.
Giuliani F; Colucci G
Oncology; 2009; 77 Suppl 1():43-9. PubMed ID: 20130431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
